Vasculitis, a severe blood vessel condition, drives the global market's growth due to advancements in biologic treatments like monoclonal antibodies. Enhanced diagnostics and personalized medicine ...

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant ...

Amgen Inc. ( NASDAQ: AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

The S&P 500 advanced 1% on Monday, June 23, 2025, as investors weighed the potential severity and impact of Iran's ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

Amgen (NASDAQ:AMGN) announced on Monday that its new weight loss treatment, MariTide, resulted in an average weight loss of ...

Amgen is expanding development plans for its weight-loss drug MariTide to study its use for heart disease and sleep apnea.